Search Results for: Clinical Roundup
-
Clinic Roundup
Regentis raised $10 million last year in a Series C financing to support clinical studies and commercial launch of GelrinC in Europe. (See BioWorld Today, May 15, 2012BioWorld Today | Thursday, April 11, 2013 -
Clinic Roundup
RP5063 also showed efficacy in the Clinical Global Impression Severity Scale and was well tolerated...The study, designated TRIG-05, is set to start enrollment this month, with a primary clinical endpoint of demonstrating efficacy, tolerability and safety...Viralytics Ltd., of Sydney, Australia, said it finalized the clinical study report on the Phase I evaluation of Cavatak, administered intravenously to late-stage melanoma, prostate, breast or colorectal cancer patients, with results showing thatBioWorld Today | Wednesday, April 10, 2013 -
MedDay Raises $10.5M for Neurological Drug R&D
The company's "exceptional team" and its potential to obtain rapid clinical efficacy data were two attractive attributes, Rafaèle Tordjman, managing partner at Sofinnova Partners, told BioWorld Today...The company plans to use the funds to move its lead program into clinical trials and to advance a second discovery program...On Tuesday, shares of StemCells (NASDAQ:STEM) gained 7 cents, closing at $1.68.By Cormac Sheridan | BioWorld Today | Wednesday, April 10, 2013 -
Financings Roundup
Canbex, a spinout of University College London, has said it expects to start clinical testing this yearBioWorld Today | Tuesday, April 9, 2013 -
Clinic Roundup
The primary endpoint of the study is the induction of clinical remission at week 12...The study is being conducted by more than 60 clinical investigators worldwide, including about 11 sites in Brazil and 24 sites in India...The TRIG-05 study is expected to begin enrollment this month, with a primary clinical endpoint of demonstrating efficacy, tolerability and safety of TI-001BioWorld Today | Tuesday, April 9, 2013 -
IPO Flurry Continues: Receptos Files Proposed $86M Offering
biotech to file for an initial public offering (IPO) this year, taking advantage of the emerging growth company provision in the Jumpstart Our Business Start-ups Act and aiming to raise as much as $86.3 million to support clinical work in multiple sclerosis, inflammatory bowel disease (IBD) and allergic/immune-mediate disorders...Funds will be used to progress the clinical development program for lead candidate, Pracinostat, its oral histone deacetylase inhibitor for advanced hematologicBy Jennifer Boggs | BioWorld Today | Monday, April 8, 2013 -
Clinic Roundup
Array BioPharma Inc., of Boulder, Colo., reported clinical data at the International Myeloma Workshop in Kyoto, Japan, showing that ARRY-520, a selective KSP inhibitor, demonstrated single-agent activity in heavily pretreated patients with relapsed or refractory multiple myeloma, with 19 months median overall survival and a 16 percent overall response rateBioWorld Today | Friday, April 5, 2013 -
Financings Roundup
Net proceeds will be used to cover costs related to the new drug application for CompleoTRT, making a milestone payment for CompleoTRT, manufacturing scale-up for CompleoTRT and Tefina clinical trialsBioWorld Today | Friday, April 5, 2013 -
Clinic Roundup
Novavax Inc., of Rockville, Md., said top-line data from its Phase II dose-ranging study testing its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age hit its protocol-specified objectives, supporting progression to the next stage of advanced clinical testingBioWorld Today | Thursday, April 4, 2013 -
Revance Adds $33M for BoNTA Alternative to Botox
Eyeing Better Mousetrap with Topical Product In 2009, Revance granted worldwide aesthetic and dermatological rights to RT002, then in preclinical studies, to Medicis Pharmaceutical Corp., of Scottsdale, Ariz., in exchange for $10 million at signing and another potential $94 million, based on clinical, regulatory and commercial milestones...The latest round is expected to support ongoing clinical development of lead candidate, LiRIS (lidocaine releasing intravesical system), in development forBy Marie Powers | BioWorld Today | Wednesday, April 3, 2013 -
Clinic Roundup
Tengion Inc., of Winston-Salem, N.C., said the firm's clinical trial application was accepted in Sweden to start a Phase I trial testing its Neo-Kidney Augment in up to five patients with advanced chronic kidney diseaseBioWorld Today | Tuesday, April 2, 2013 -
Vivus Plays for Time; Enters $110M Capped Royalty Deal
Net proceeds totaled $12 million and will be used to fund R&D and clinical trials, acquisition of intellectual property and other purposes...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.By Catherine Shaffer | BioWorld Today | Wednesday, March 27, 2013 -
Financings Roundup
During that period, MedBridge also will provide full administrative support for the company, allowing it to focus on clinical development of the therapeutic pipelineBioWorld Today | Monday, March 25, 2013 -
Clinic Roundup
Benitec Biopharma Ltd., of Sydney, Australia, selected the Duke Clinical Research Unit in Durham, N.C., as a site for its upcoming Phase I/II first-in-human trial of TT-034 in hepatitis C virus (HCV...NeuroVive Pharmaceutical AB, of Lund, Sweden, said the 600th patient was recruited in its pivotal Phase III European, multicenter CIRCUS (does Cyclosporine ImpRove Clinical oUtcome in ST elevation myocardial infarction patients) trial assessing CicloMulsion in heart reperfusion injury followingBioWorld Today | Monday, March 25, 2013 -
Enanta Raises $56M in IPO; Soars on First Day Trading
Another $406 million could come in the form of clinical, regulatory and commercial milestones, and Enanta would be eligible for tiered, double-digit royalties and a U.S...Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate purposes...Trimel's pipeline includes CompleoTRT, a bioadhesive intranasal testosterone gel for male hypogonadism.By Jennifer Boggs | BioWorld Today | Friday, March 22, 2013 -
Clinic Roundup
The company also is preparing a clinical program for marketing in Europe and the U.SBioWorld Today | Thursday, March 21, 2013 -
Antibiotic Developer Tetraphase Prices Initial Public Offering
The German Federal State of Saxony and the European Union funded the grant, which supplements a grant awarded by the SAB in August 2011 for the CANVAS clinical trial...Net proceeds of about $12 million will be used to support R&D, acquisition of intellectual property related to complementary drug therapies, clinical trials and other expenses...The first tranche of the Series B closed in June 2012 for $8.6 million.By Peter Winter | BioWorld Today | Thursday, March 21, 2013 -
Clinic Roundup
The NX03-0040 prostate cancer clinical study of 150 men is testing low (2.5 mg) and high (15 mg) single doses of NX-1207 for the effect to eradicate or shrink low-grade localized prostate cancer tumorsBioWorld Today | Wednesday, March 20, 2013 -
Clinic Roundup
Secondary objectives of the trial include clinical activity by serum TTR levels...The study showed that Uceris 9 mg gave a statistically significant benefit over placebo for the primary endpoint of clinical and endoscopic remission at week eight...For the Uceris 9-mg group, 17.4 percent of patients achieved clinical and endoscopic remission, compared to 4.5 percent of the placebo group (p = 0.0047BioWorld Today | Tuesday, March 19, 2013 -
Clinic Roundup
The company also said it is initiating a new financing round – about $6 million in new convertible debt – to fund further clinical developmentBioWorld Today | Monday, March 18, 2013
Category
Current Filters
- xNOT New York
Related Keywords
Categories
- x BioWorld Today (1942)
- x BioWorld International (48)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.